A six month double-blind, placebo-controlled trial followed by a six month open-label study of the early administration of alendronate [alendronic acid] on prevention of bone loss after hip fracture
Phase of Trial: Phase III
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Alendronic acid (Primary)
- Indications Osteoporosis
- Focus Therapeutic Use
- 04 Dec 2006 New trial record.